HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis.

Abstract
The present study was performed to clarify the mechanism underlying the beneficial effects of lisinopril on chronic glomerulonephritis. Chronic glomerulonephritis was induced by a single injection of E30 monoclonal antibody (E30) recognizing Thy-1.1 antigen to unilaterally nephrectomized rats. E30 injection resulted in persistent massive proteinuria with a decrease in anionic charge sites on the glomerular basement membrane (GBM) at 8 weeks. Also, renal tissue from rats treated with E30 showed typical glomerulosclerosis and tubulointerstitial fibrosis. Lisinopril exerted a potent antiproteinuric effect and suppressed the progression of both glomerulosclerosis and tubulointerstitial fibrosis. Lisinopril recovered the reduced number of anionic charge sites on GBM, accounting for the positive action against massive proteinuria. Immunostaining for desmin revealed that lisinopril treatment prevented the injury of glomerular epithelial cells (GECs) occurring in the chronic nephritic stage. Also, the level of gene expression of transforming growth factor-beta (TGF-beta) and plasminogen activator inhibitor-1 (PAI-1) in the renal cortex were reduced, suggesting that lisinopril improved extracellular matrix (ECM) metabolism. These results indicated that proteinuria in Thy-1.1 antibody-induced chronic nephritis is associated with a decrease in anionic charge sites on GBM, and that the antiproteinuric effect of lisinopril is attributable to protection against GEC damage. Suppression of TGF-beta and PAI-1 expression contributed to the preventive effect of lisinopril on ECM deposition in renal tissue.
AuthorsToshihiro Shinosaki, Ikuko Miyai, Yasuharu Nomura, Tatsuo Kobayashi, Norio Sunagawa, Hidetake Kurihara
JournalNephron (Nephron) Vol. 91 Issue 4 Pg. 719-29 (Aug 2002) ISSN: 1660-8151 [Print] Switzerland
PMID12138278 (Publication Type: Journal Article)
CopyrightCopyright 2002 S. Karger AG, Basel
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • DNA Primers
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Transforming Growth Factor beta
  • Lisinopril
Topics
  • Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
  • Animals
  • Base Sequence
  • DNA Primers
  • Immunohistochemistry
  • Kidney Glomerulus (ultrastructure)
  • Lisinopril (therapeutic use)
  • Male
  • Microscopy, Electron
  • Nephritis (drug therapy)
  • Plasminogen Activator Inhibitor 1 (genetics)
  • RNA, Messenger (genetics)
  • Rats
  • Rats, Wistar
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transforming Growth Factor beta (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: